All issues > Volume 0(0);

Original article

Efficacy of leuprolide acetate versus triptorelin pamoate administered every 3 months for treatment of central precocious puberty

Thanaporn Thaneetrakool¹, Suphab Aroonparkmongkol¹, Nattakarn Numsriskulrat^1,2, Vichit Supornsilchai¹, Suttipong Wacharasindhu¹, Khomsak Srilanchakon¹ 

¹Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of medicine, Chulalongkorn University, Bangkok, Thailand
²Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Correspondence Khomsak Srilanchakon ,Email: khomsak_s@hotmail.com

Received: May 17, 2024; Revised: July 14, 2024   Accepted: July 14, 2024.

Abstract

Background
Central precocious puberty (CPP) is typically treated with gonadotropin-releasing hormone (GnRH) agonists. Although numerous GnRH agonist variants are available, limited research has compared the efficacy of leuprolide acetate and triptorelin pamoate administered at 3-month intervals.
Purpose
This study aimed to assess the efficacy of CPP treatment with triptorelin pamoate and leuprolide acetate administered at 3-month intervals.
Methods
This retrospective cohort study included 116 girls with CPP: 71 treated with leuprolide acetate every 3 months and 45 treated with triptorelin pamoate every 3 months. Anthropometric measurements were compared before and after therapy. At 6 months after the therapy, luteinizing hormone (LH) suppression was evaluated.
Results
When administered every 3 months, leuprolide acetate and triptorelin pamoate significantly suppressed LH. The predicted adult height (PAH) and degree of bone age advancement at the end of treatment were comparable.
Conclusion
Treatment with leuprolide acetate and triptorelin pamoate every 3 months did not have significantly different effects on LH suppression or PAH.

Keywords :Efficacy, Leuprolide acetate, Triptorelin pamoate, 3-Monthly GnRH agonist, Central precocious puberty